[{"id":"ba15135a-7176-4f0e-a8cc-e6c040cf6509","acronym":"","url":"https://clinicaltrials.gov/study/NCT04574583","created_at":"2021-01-18T21:50:28.241Z","updated_at":"2025-02-25T17:00:40.932Z","phase":"Phase 1/2","brief_title":"Phase I/II Trial Investigating the Safety, Tolerability, Pharmacokinetics, Immune and Clinical Activity of SX-682 in Combination With BinTrafusp Alfa (M7824 or TGF-beta \"Trap\"/PD-L1) With CV301 TRICOM in Advanced Solid Tumors (STAT)","source_id_and_acronym":"NCT04574583","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" HER-2 • PD-L1 • ER • PGR • CD4","pipe":" | ","alterations":" HER-2 amplification • HER-2 negative","tags":["HER-2 • PD-L1 • ER • PGR • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 amplification • HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e bintrafusp alfa (M7824) • SX-682 • Panvac-VF (falimarev/inalimarev)"],"overall_status":"Completed","enrollment":" Enrollment 12","initiation":"Initiation: 11/24/2020","start_date":" 11/24/2020","primary_txt":" Primary completion: 02/07/2023","primary_completion_date":" 02/07/2023","study_txt":" Completion: 05/19/2023","study_completion_date":" 05/19/2023","last_update_posted":"2025-02-03"},{"id":"f86dd180-9964-44e8-9f7d-13e77891a73a","acronym":"STOPTRAFFIC-1","url":"https://clinicaltrials.gov/study/NCT04599140","created_at":"2021-02-21T15:52:40.898Z","updated_at":"2025-02-25T14:29:40.279Z","phase":"Phase 1/2","brief_title":"SX-682 and Nivolumab for the Treatment of RAS-Mutated, MSS Unresectable or Metastatic Colorectal Cancer, the STOPTRAFFIC-1 Trial","source_id_and_acronym":"NCT04599140 - STOPTRAFFIC-1","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" BRAF • CD8 • CD4 • CD69 • IRF2","pipe":"","alterations":" ","tags":["BRAF • CD8 • CD4 • CD69 • IRF2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • SX-682"],"overall_status":"Recruiting","enrollment":" Enrollment 53","initiation":"Initiation: 10/14/2020","start_date":" 10/14/2020","primary_txt":" Primary completion: 01/31/2026","primary_completion_date":" 01/31/2026","study_txt":" Completion: 01/31/2026","study_completion_date":" 01/31/2026","last_update_posted":"2025-01-17"},{"id":"74a856b5-259a-4d5c-9166-0007d61a1cb7","acronym":"","url":"https://clinicaltrials.gov/study/NCT05570825","created_at":"2022-10-07T15:08:08.992Z","updated_at":"2024-07-02T16:35:05.631Z","phase":"Phase 2","brief_title":"SX-682 With Pembrolizumab for the Treatment of Metastatic or Recurrent Stage IIIC or IV Non-Small Cell Lung Cancer","source_id_and_acronym":"NCT05570825","lead_sponsor":"University of Washington","biomarkers":" PD-L1 • ALK • RET • ROS1","pipe":" | ","alterations":" PD-L1 expression • RET fusion • ALK rearrangement • ROS1 fusion • ROS1 rearrangement • RET rearrangement","tags":["PD-L1 • ALK • RET • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • RET fusion • ALK rearrangement • ROS1 fusion • ROS1 rearrangement • RET rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • SX-682 • Pembroria (pembrolizumab biosimilar)"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 04/06/2023","start_date":" 04/06/2023","primary_txt":" Primary completion: 07/01/2027","primary_completion_date":" 07/01/2027","study_txt":" Completion: 07/01/2028","study_completion_date":" 07/01/2028","last_update_posted":"2024-05-07"},{"id":"52cec249-3dea-47ff-af14-c5976f1922da","acronym":"","url":"https://clinicaltrials.gov/study/NCT05604560","created_at":"2022-11-03T14:56:55.660Z","updated_at":"2024-07-02T16:35:14.598Z","phase":"Phase 2","brief_title":"A Neoadjuvant Study of Tislelizumab and SX-682 for Resectable Pancreas Cancer","source_id_and_acronym":"NCT05604560","lead_sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","biomarkers":" TNFRSF9 • GZMB","pipe":"","alterations":" ","tags":["TNFRSF9 • GZMB"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tevimbra (tislelizumab-jsgr) • SX-682"],"overall_status":"Recruiting","enrollment":" Enrollment 25","initiation":"Initiation: 11/08/2023","start_date":" 11/08/2023","primary_txt":" Primary completion: 09/01/2026","primary_completion_date":" 09/01/2026","study_txt":" Completion: 09/01/2026","study_completion_date":" 09/01/2026","last_update_posted":"2024-03-15"}]